You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

isatuximab

Showing 1 - 25 of 37
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Antibody-mediated Rejection, Allosensitization Trial in New York (Isatuximab, bone marrow biopsy)

Not yet recruiting
  • Antibody-mediated Rejection
  • Allosensitization
  • Isatuximab
  • bone marrow biopsy
  • New York, New York
    NYU Langone Health
May 16, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Isatuximab
  • +3 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Houston, Texas
    M D Anderson Cancer Center
Mar 8, 2023

Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Isatuximab
  • +3 more
  • (no location specified)
Feb 3, 2023

Amyloidosis, Light Chain (AL) Amyloidosis Trial (Bendamustine Hydrochloride, Isatuximab)

Withdrawn
  • Amyloidosis
  • Light Chain (AL) Amyloidosis
  • Bendamustine Hydrochloride
  • Isatuximab
  • (no location specified)
Dec 29, 2022

Monoclonal Gammopathy Trial in New York, Philadelphia (Isatuximab)

Recruiting
  • Monoclonal Gammopathy
  • Isatuximab
  • Boston, Massachusetts
  • +1 more
Nov 16, 2022

Multiple Myeloma Trial in Stockholm (CellProtect, Isatuximab)

Recruiting
  • Multiple Myeloma
  • Stockholm, Sweden
    Karolinska University Hospital, Huddinge
Aug 16, 2022

Multiple Myeloma Trial in Saint Louis (Isatuximab, Bendamustine, Prednisone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Sep 21, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Isatuximab
  • +3 more
  • Poitiers, France
    CHU Poitiers
Jan 9, 2023

Immunological Pure Red Cell Aplasia Trial (Isatuximab)

Not yet recruiting
  • Immunological Pure Red Cell Aplasia
  • Isatuximab
  • (no location specified)
Sep 26, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Isatuximab
  • +2 more
  • Chapel Hill, North Carolina
  • +2 more
Jun 9, 2023

Multiple Myeloma Trial (Isatuximab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Apr 19, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Multiple Myeloma Trial in Saint Louis (Isatuximab, Bortezomib, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 4, 2022

Multiple Myeloma Trial (Dexamethasone, Isatuximab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jan 10, 2023

Multiple Myeloma, Myeloma Trial in Poitiers (Isatuximab, Lenalidomide, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Myeloma
  • Isatuximab
  • +3 more
  • Poitiers, France
    CHU Poitiers
Sep 5, 2022

Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma Trial in New York (Isatuximab, Standard Procedures)

Recruiting
  • Lymphoma
  • +3 more
  • Isatuximab
  • Standard Procedures
  • New York, New York
    Columbia University
Apr 27, 2022

Multiple Myeloma, Renal Impairment, Tumors, Plasma Cell Trial in Greece (Isatuximab, Bortezomib, Cyclophosphamide)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Isatuximab
  • +4 more
  • Athens, Greece
  • +5 more
Mar 28, 2022

Multiple Myeloma Trial in United States (Isatuximab, Carfilzomib, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • San Francisco, California
  • +3 more
Dec 24, 2022

Multiple Myeloma Trial in Chicago, Milwaukee (Bortezomib, Isatuximab, Cyclophosphamide)

Recruiting
  • Multiple Myeloma
  • Chicago, Illinois
  • +1 more
Mar 14, 2022

Multiple Myeloma, Cancer Trial in Chapel Hill, Durham, Columbus (Isatuximab, Lenalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Cancer
  • Isatuximab
  • +2 more
  • Chapel Hill, North Carolina
  • +2 more
Jun 30, 2022

AL Amyloidosis Trial in France (Isatuximab)

Recruiting
  • AL Amyloidosis
  • Isatuximab
  • Amiens, France
  • +14 more
Aug 9, 2022

Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +3 more
  • Aachen, Germany
  • +29 more
Apr 4, 2023

Newly Diagnosed Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)

Not yet recruiting
  • Newly Diagnosed Multiple Myeloma
  • Isatuximab
  • +4 more
  • Hamburg, Germany
  • +3 more
Dec 16, 2022